New Clinical Trial To Assess Long-Term Therapy Efficacy for Perianal Fistulas in CD Patients

New Clinical Trial To Assess Long-Term Therapy Efficacy for Perianal Fistulas in CD Patients
In a new study entitled “Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement platy (PISA): study protocol for a randomized controlled trial,” authors present the protocol for a new, randomized multicenter control trial to assess the efficacy between current three lines of therapy for Crohn’s disease patients with perianal fistulas. The study was published in the journal Trials. Crohn’s disease (CD), together with ulcerative colitis (UC), is the most common type of Inflammatory Bowel Disease (IBD), estimated to affect 1.4 million Americans. Up to 25% of all CD patients develop fistulas, more commonly perianal fistulas – a very disabling manifestation (associated with local pain, discharge) and source of morbidity for CD patients (including sphincter and perineal tissue destruction). Treatment for high complex fistulas has relied in the past years on surgical procedures, either surgical seton placement for chronic drainage of the fistula or closure of the internal fistula opening by creating an advancement plasty. However, these methods were reported to negatively influence patients’ quality of life or required re-interventions, respectively. Introducing anti-TNF agents (infliximab and adalimumab) shifted patients’ treatment from surgical procedures to almost exclusive anti-TNF -based therapies. The efficacy of this treatment on the long run and its level of efficacy compared to previous surgical methods
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *